{"id":169478,"date":"2025-07-29T02:45:21","date_gmt":"2025-07-29T06:45:21","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169478"},"modified":"2025-07-29T02:45:21","modified_gmt":"2025-07-29T06:45:21","slug":"torrent-pharmaceuticals-ltd-q1fy26-earnings-results-20-rise-in-profits","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q1fy26-earnings-results-20-rise-in-profits\/","title":{"rendered":"Torrent Pharmaceuticals Ltd Q1FY26 Earnings Results &#8211; 20% rise in Profits"},"content":{"rendered":"<p>Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.<\/p>\n<h2 id=\"q1-fy26-earnings-summary-aprjun-2025\" class=\"mb-2 mt-6 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Q1 FY26 Earnings Summary (Apr\u2013Jun 2025)<\/h2>\n<ul class=\"marker:text-textOff list-disc\">\n<li>\n<p class=\"my-0\"><strong>Revenue:<\/strong>\u00a0\u20b93,178 crore, up 11.2% YoY (Q1 FY25: \u20b92,859 crore).<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Net Profit (PAT):<\/strong>\u00a0\u20b9548 crore, up 20% YoY (Q1 FY25: \u20b9457 crore).<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>EBITDA:<\/strong>\u00a0\u20b91,032 crore, up 14% YoY (Q1 FY25: \u20b9904 crore).<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Margin:<\/strong>\u00a0Improved to 32.5% from 31.6% YoY.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>India Business:<\/strong>\u00a0\u20b91,811 crore, up 11% YoY, driven by outperformance in focus therapies. Chronic segment grew 13%.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>US Business:<\/strong>\u00a0Revenue \u20b9308 crore, up 19% YoY; recent launches achieved targeted market shares.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Germany &amp; Brazil:<\/strong>\u00a0Germany revenue up 9% YoY to \u20b9308 crore. Brazil portfolio revenue up 11% to \u20b9218 crore.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Outlook:<\/strong>\u00a0Analysts continue to rate the stock favorably; consensus price targets with modest upside<span class=\"whitespace-nowrap\">.<\/p>\n<p><\/span><\/p>\n<\/li>\n<\/ul>\n<h3 id=\"key-management--strategic-decisions\" class=\"mb-2 mt-6 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Key Management &amp; Strategic Decisions<\/h3>\n<ul class=\"marker:text-textOff list-disc\">\n<li>\n<p class=\"my-0\"><strong>Leadership Transition:<\/strong>\u00a0Appointment of Aman Mehta as MD from August 2025, ensuring generational leadership and continuity.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Growth Investment:<\/strong>\u00a0Planned fundraise to support R&amp;D, M&amp;A, and pipeline development in India and export markets.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Expansion:<\/strong>\u00a0Recent product launches in the US achieving targeted market share; focus continues on India, Brazil, Germany.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>R&amp;D Focus:<\/strong>\u00a0Increasing <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/3499cf77-9c07-48a2-90f7-79c0f6a48c47.pdf\" target=\"_blank\" rel=\"noopener\">R&amp;D allocation to 5\u20136% of revenues<\/a> in FY26 to support innovation and complex generics.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Cost &amp; Efficiency:<\/strong>\u00a0<a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/3499cf77-9c07-48a2-90f7-79c0f6a48c47.pdf\" target=\"_blank\" rel=\"noopener\">Continued margin improvement<\/a> through operational leverage and scale.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Dividend Policy:<\/strong>\u00a0Maintains high shareholder returns via dividends.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Strategic Acquisitions:<\/strong>\u00a0Recent acquisition in the sector to diversify and strengthen specialty product offering.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Therapy Leadership:<\/strong>\u00a0Targeting market leadership in chronic diseases (cardiac, diabetes, CNS) in India and selective global markets.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-169479\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-13-839x1024.png\" alt=\"\" width=\"640\" height=\"781\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-13-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-13-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-13-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-13-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-13.png 1489w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"q4-fy25-earnings-summary-janmar-2025\" class=\"mb-2 mt-6 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Q4 FY25 Earnings Summary (Jan\u2013Mar 2025)<\/h2>\n<ul class=\"marker:text-textOff list-disc\">\n<li>\n<p class=\"my-0\"><strong>Revenue:<\/strong>\u00a0\u20b92,959 crore, up 7.8% YoY.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Net Profit (PAT):<\/strong>\u00a0\u20b9498 crore, up 11% YoY (Q4 FY24: \u20b9449 crore).<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>EBITDA:<\/strong>\u00a0\u20b9964 crore, up 9% YoY; EBITDA margin expanded to 32.6% from 32.2%.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>EPS:<\/strong>\u00a0Approximately \u20b914.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Gross Margin:<\/strong>\u00a075.3%.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Profit Driver:<\/strong>\u00a0Growth led by robust India business and margin improvement.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Exceptional Items:<\/strong>\u00a0Adjusted PAT growth for Q4 FY25 is 15% when excluding exceptional charges related to the closure of DPCO litigation.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>R&amp;D Investment:<\/strong>\u00a0\u20b9581 crore for FY25, making up 5% of revenues (+10% YoY).<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Dividend:<\/strong>\u00a0Recommended a final dividend of \u20b96\/share (face value \u20b95) and distributed \u20b926\/share interim dividend in FY25.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Fundraise Plan:<\/strong>\u00a0Board approved proposal to raise up to \u20b95,000 crore via shares\/convertibles (subject to shareholder approval).<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Leadership:<\/strong>\u00a0Aman Mehta (Whole-Time Director) named as new Managing Director, effective August 1, 2025, pending AGM approval.<\/p>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. Q1 FY26 Earnings Summary (Apr\u2013Jun 2025) Revenue:\u00a0\u20b93,178 crore, up 11.2% YoY (Q1 FY25: \u20b92,859 crore). Net Profit (PAT):\u00a0\u20b9548 crore, up 20% YoY (Q1 FY25: \u20b9457 crore). EBITDA:\u00a0\u20b91,032 crore, up 14% YoY (Q1 FY25: [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":169479,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[11776,1115],"class_list":["post-169478","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-healthcare-stocks","tag-active-pharmaceutical-ingredients","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/2-13.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":172440,"url":"https:\/\/alphastreet.com\/india\/torrent-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":169478,"position":0},"title":"Torrent Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 17, 2025","format":false,"excerpt":"Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. \u00a0 Q2 FY26 Earnings Results: Revenue from Operations: \u20b93,302 crore, up 14% YoY from \u20b92,889 crore EBITDA: \u20b91,083 crore, up 15.3% YoY; EBITDA margin expanded to 32.8% (from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Torrent Pharmaceuticals Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":169478,"position":1},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169548,"url":"https:\/\/alphastreet.com\/india\/strides-pharma-science-ltd-q1-fy26-earnings-results-97-fall-in-profits\/","url_meta":{"origin":169478,"position":2},"title":"Strides Pharma Science Ltd Q1 FY26 Earnings Results &#8211; 97% fall in Profits","author":"Chirag Gupta","date":"July 30, 2025","format":false,"excerpt":"Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company's pharmaceutical products are sold in over 100 countries. The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169742,"url":"https:\/\/alphastreet.com\/india\/glaxosmithkline-pharmaceuticals-ltd-q1-fy26-earnings-results-revenue-down-1-net-profit-rises-13-yoy\/","url_meta":{"origin":169478,"position":3},"title":"GlaxoSmithKline Pharmaceuticals Ltd Q1 FY26 Earnings Results \u2013 Revenue Down 1%, Net Profit Rises 13% YoY","author":"Divyansh_Kasana","date":"August 4, 2025","format":false,"excerpt":"GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) is a leading pharmaceutical company focused on researching, manufacturing, and making available a broad range of medicines and vaccines that benefit people in India and globally. The company consistently delivers innovation and quality across its therapeutic portfolio. (Source: Company Website) Q1 FY26 Earnings Summary (Apr\u2013Jun\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169792,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q1-fy26-earnings-results-51-rise-in-profits\/","url_meta":{"origin":169478,"position":4},"title":"Lupin Ltd Q1 FY26 Earnings Results &#8211; 51% rise in Profits","author":"Chirag Gupta","date":"August 6, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lupin Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169622,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy26-earnings-results-20-fall-in-profits\/","url_meta":{"origin":169478,"position":5},"title":"Sun Pharmaceutical Industries Ltd Q1 FY26 Earnings Results &#8211; 20% fall in Profits","author":"Chirag Gupta","date":"July 31, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169478"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169478\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/169479"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}